FDA Bids Farewell to Cepheid's COVID Test Era
Published Date: 6/26/2025
Notice
Summary
The FDA is ending the emergency approval for Cepheid’s Xpert Xpress COVID-19 test because the company asked them to. This means the test can no longer be used under emergency rules, so labs and healthcare providers need to switch to other authorized tests. No extra costs or deadlines for the public, but it’s a heads-up for anyone using this test.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Cepheid Xpert Xpress EUA Revoked
The FDA revoked the Emergency Use Authorization for Cepheid’s Xpert Xpress SARS-CoV-2 test at the company's request. That means labs and health care providers can no longer use this test under emergency rules and must switch to other authorized COVID-19 tests.
No Public Costs or Deadlines
The FDA says there are no extra costs or new deadlines for the public because of this revocation. This notice is mainly a heads-up for people and organizations that were using the Cepheid test.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2025-11820 — Public Water System Supervision Program Revision for New York; Notice of Approval and Opportunity for Public Comment and Public Hearing
New York updated its water safety rules to better control harmful chemicals in drinking water. The EPA says these changes meet all federal standards and is ready to approve them. If you live in New York or care about clean water, you can share your thoughts or ask for a public hearing soon.
Next: 2025-11823 — Meeting of the Interagency Task Force on Veterans Small Business Development
The Interagency Task Force on Veterans Small Business Development is meeting soon to discuss new ways to help veteran-owned small businesses grow and succeed. If you’re a veteran entrepreneur, this means fresh ideas and support could be on the way, with updates coming soon. Stay tuned for opportunities that might boost your business and open doors to new resources!